ALEMBIC PHARMA share price has zoomed 6% and is presently trading at Rs 1,250.0.
Meanwhile, the BSE HEALTHCARE index is at 43,909.9 (down 0.8%).
Among the top gainers in the BSE HEALTHCARE index today are GRANULES INDIA (up 3.0%) and ERIS LIFESCIENCES (up 2.1%).
J.B.Chemicals (down 3.8%) and APOLLO HOSPITALS (down 3.7%) are among the top losers today.
Over the last one year, ALEMBIC PHARMA has moved up from Rs 790.9 to Rs 1,250.0, registering a gain of Rs 459.2 (up 58.1%).
On the other hand, the BSE HEALTHCARE index has moved up from 28,428.9 to 43,909.9, registering a gain of 54.5% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 161.5%), SUVEN PHARMACEUTICALS (up 108.4%) and Glenmark Pharma (up 97.2%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 82,890.6 (down 1.6%).
The top losers among the BSE Sensex today are Asian Paints (down 3.8%) and Tata Motors (down 3.7%). The most traded stocks in the BSE Sensex are HDFC Bank and Reliance Ind..
In the meantime, NSE Nifty is at 25,387.4 (down 1.6%). BPCL and IOC are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,512.1 to 82,890.6, registering a gain of 17,378.5 points (up 26.5%).
ALEMBIC PHARMA net profit grew 11.3% YoY to Rs 1,342 million for the quarter ended June 2024, compared to a profit of Rs 1,206 million a year ago. Net sales rose 5.1% to Rs 15,617 million during the period as against Rs 14,862 million in April-June 2023.
For the year ended March 2024, ALEMBIC PHARMA reported 80.1% increase in net profit to Rs 6,158 million compared to net profit of Rs 3,420 million during FY23. Revenue of the company grew 10.2% to Rs 62,286 million during FY24.
The current Price to earnings ratio of ALEMBIC PHARMA, based on rolling 12 month earnings, stands at 39.0.
Equitymaster requests your view! Post a comment on "ALEMBIC PHARMA Gains 6%; BSE HEALTHCARE Index Down 0.8%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!